DK1154796T3 - Nye albuminfrie Faktor VIII-formuleringer - Google Patents

Nye albuminfrie Faktor VIII-formuleringer

Info

Publication number: DK1154796T3
Authority: DK; Denmark
Prior art keywords: factor viii; group; agent selected; raffinose; trehalose
Prior art date: 1999-02-22

Application number

DK00907322T

Other languages

Danish (da)

English (en)

Inventor

Marc Besman

Erik Bjornson

Feroz Jameel

Ramesh Kashi

Michael Pikal

Serguei Tchessalov

John Carpenter

Original Assignee

Univ Connecticut

Baxter Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-22

Filing date

2000-02-22

Publication date

2007-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26944588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1154796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-02-22 Application filed by Univ Connecticut, Baxter Int filed Critical Univ Connecticut

2007-09-24 Application granted granted Critical

2007-09-24 Publication of DK1154796T3 publication Critical patent/DK1154796T3/da

Links

239000000203 mixture Substances 0.000 title abstract 5
238000009472 formulation Methods 0.000 title abstract 4
102000001690 Factor VIII Human genes 0.000 title abstract 3
108010054218 Factor VIII Proteins 0.000 title abstract 3
229960000301 factor viii Drugs 0.000 title abstract 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 6
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 3
239000004475 Arginine Substances 0.000 abstract 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 3
229930006000 Sucrose Natural products 0.000 abstract 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
239000006172 buffering agent Substances 0.000 abstract 3
159000000007 calcium salts Chemical class 0.000 abstract 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 3
239000011780 sodium chloride Substances 0.000 abstract 3
239000003381 stabilizer Substances 0.000 abstract 3
239000005720 sucrose Substances 0.000 abstract 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
102000009027 Albumins Human genes 0.000 abstract 1
108010088751 Albumins Proteins 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
229920001612 Hydroxyethyl starch Polymers 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
239000004067 bulking agent Substances 0.000 abstract 1
229940050526 hydroxyethylstarch Drugs 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DK00907322T 1999-02-22 2000-02-22 Nye albuminfrie Faktor VIII-formuleringer DK1154796T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25527999A	1999-02-22	1999-02-22
US45275299A	1999-12-01	1999-12-01
PCT/US2000/040068 WO2000048635A1 (en)	1999-02-22	2000-02-22	Novel albumin-free factor viii formulations

Publications (1)

Publication Number	Publication Date
DK1154796T3 true DK1154796T3 (da)	2007-09-24

Family

ID=26944588

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK00907322T DK1154796T3 (da)	1999-02-22	2000-02-22	Nye albuminfrie Faktor VIII-formuleringer
DK06077229.0T DK1820516T3 (da)	1999-02-22	2000-02-22	Nye albuminfrie faktor VIII-præparater
DK09075396.3T DK2130554T3 (da)	1999-02-22	2000-02-22	Albuminfrie faktor VIII-præparater
DK10075019.9T DK2193809T3 (en)	1999-02-22	2000-02-22	The albumin-free Factor VIII formulation

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK06077229.0T DK1820516T3 (da)	1999-02-22	2000-02-22	Nye albuminfrie faktor VIII-præparater
DK09075396.3T DK2130554T3 (da)	1999-02-22	2000-02-22	Albuminfrie faktor VIII-præparater
DK10075019.9T DK2193809T3 (en)	1999-02-22	2000-02-22	The albumin-free Factor VIII formulation

Country Status (19)

Country	Link
US (8)	US6586573B1 (de)
EP (5)	EP2921180B1 (de)
JP (9)	JP5149470B2 (de)
CN (3)	CN101810854A (de)
AT (1)	ATE365052T1 (de)
AU (1)	AU777972B2 (de)
BR (1)	BR0008405B1 (de)
CA (4)	CA2362927C (de)
CY (2)	CY1108030T1 (de)
CZ (3)	CZ307715B6 (de)
DE (1)	DE60035260T2 (de)
DK (4)	DK1154796T3 (de)
ES (4)	ES2394755T3 (de)
HK (1)	HK1213801A1 (de)
MX (1)	MXPA01008515A (de)
PL (4)	PL203177B1 (de)
PT (4)	PT1820516E (de)
RU (1)	RU2244556C2 (de)
WO (1)	WO2000048635A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7253262B2 (en) *	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
US7244824B2 (en) *	1995-01-19	2007-07-17	Quadrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
US6214054B1 (en)	1998-09-21	2001-04-10	Edwards Lifesciences Corporation	Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
EP2921180B1 (de)	1999-02-22	2019-08-14	University of Connecticut	Albuminfreie Faktor-VIII-Formulierungen
US6830917B2 (en) *	2001-12-10	2004-12-14	Baxter Healthcare S.A.	Method of isolation and purification of trypsin from pronase protease and use thereof
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351756A1 (en) *	2001-12-21	2003-07-15	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
US6878168B2 (en)	2002-01-03	2005-04-12	Edwards Lifesciences Corporation	Treatment of bioprosthetic tissues to mitigate post implantation calcification
US6982080B2 (en) *	2002-03-15	2006-01-03	Wyeth	Hydroxyethyl starch—containing polypeptide compositions
GB0207092D0 (en)	2002-03-26	2002-05-08	Sod Conseils Rech Applic	Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
PT1517698E (pt)	2002-06-21	2014-11-19	Novo Nordisk Healthcare Ag	Composições sólidas estabilizadas de polipéptidos do fator viia
GB0304636D0 (en) *	2003-02-28	2003-04-02	Britannia Pharmaceuticals Ltd	Pharmaceutical composition for nasal delivery
RU2005132164A (ru) *	2003-03-18	2006-06-10	Ново Нордиск Хелт Кэр Аг (Ch)	Жидкие, водные фармацевтические композиции полипептидов фактора vii
US7897734B2 (en) *	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
KR20060015574A (ko) *	2003-05-23	2006-02-17	노보 노르디스크 헬스 케어 악티엔게젤샤프트	용액 중 단백질 안정화
WO2004112828A1 (en) *	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
EP1644030B1 (de) *	2003-07-01	2009-10-28	Novo Nordisk Health Care AG	Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
MXPA06001283A (es) *	2003-08-05	2006-04-11	Novo Nordisk As	Derivados de insulina novedosos.
KR100560697B1 (ko) *	2003-08-06	2006-03-16	씨제이 주식회사	알부민을 함유하지 않는 에리스로포이에틴 제제
ES2574581T3 (es)	2003-08-14	2016-06-20	Novo Nordisk Health Care Ag	Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
CZ300795B6 (cs) *	2003-09-02	2009-08-12	Pliva-Lachema A. S.	Farmaceutická kompozice a zpusob její výroby
JP2007505147A (ja) *	2003-09-12	2007-03-08	アンティジェニクスインコーポレーテッド	単純ヘルペスウイルス感染の治療および予防用ワクチン
RU2373953C2 (ru) *	2003-12-19	2009-11-27	Ново Нордиск Хелс Кеа Аг	Стабилизированная композиция, содержащая полипептид фактора vii
GB0404586D0 (en) *	2004-03-01	2004-04-07	Britannia Pharmaceuticals Ltd	Improvements in or relating to organic materials
EP1720519A1 (de) *	2004-03-04	2006-11-15	Wyeth	Lyophilisationsverfahren zur verbesserung der kristallisation von hilfsstoffen
CA2557061C (en) *	2004-03-19	2013-08-20	Baxter International Inc.	Factor ixa for the treatment of bleeding disorders
US7319032B2 (en) *	2004-04-22	2008-01-15	Medtox	Non-sugar sweeteners for use in test devices
KR100624013B1 (ko) *	2004-06-25	2006-09-19	주식회사 녹십자홀딩스	동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
CA2591852A1 (en)	2004-12-27	2006-07-06	Baxter International Inc.	Polymer-von willebrand factor-conjugates
FR2881139A1 (fr) *	2005-01-26	2006-07-28	Agronomique Inst Nat Rech	Composition pour la lyophilisation de proteines
ES2390354T3 (es) *	2005-07-22	2012-11-12	Amgen, Inc	Liofilizados de proteínas concentrados, procedimientos y usos
UA97234C2 (ru)	2005-11-01	2012-01-25	Уайєт	Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
EP2175273B1 (de) *	2005-11-09	2013-09-04	Ajinomoto Co., Inc.	Kokumi-Verleihungsmittel
EP2233137B1 (de) *	2005-11-09	2014-04-30	Ajinomoto Co., Inc.	Kalziumrezeptor-Aktivator
US8420144B2 (en) *	2005-11-09	2013-04-16	Ajinomoto Co., Inc.	Kokumi-imparting agent, method of using, and compositions containing same
CN101312744A (zh) *	2005-11-22	2008-11-26	惠氏公司	免疫球蛋白融合蛋白制剂
JP4808785B2 (ja)	2005-12-28	2011-11-02	ノボ・ノルデイスク・エー／エス	インスリン組成物および組成物の製造方法
CA2647314A1 (en)	2006-03-31	2007-11-08	Baxter International Inc.	Pegylated factor viii
US7982010B2 (en)	2006-03-31	2011-07-19	Baxter International Inc.	Factor VIII polymer conjugates
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
US7985839B2 (en)	2006-03-31	2011-07-26	Baxter International Inc.	Factor VIII polymer conjugates
ES2386972T3 (es) *	2006-05-31	2012-09-10	Genzyme Corporation	Uso de polisacáridos para la estimulación de la actividad enzimática
WO2008073582A2 (en)	2006-10-27	2008-06-19	Edwards Lifesciences Corporation	Biological tissue for surgical implantation
CL2007003209A1 (es)	2006-11-07	2008-05-09	Acambis Inc	Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
CA2670618C (en)	2006-12-15	2016-10-04	Baxter International Inc.	Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
FR2913020B1 (fr)	2007-02-23	2012-11-23	Biomethodes	Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP2117514B1 (de) *	2007-03-05	2011-06-15	Cadila Healthcare Limited	Zusammensetzungen mit peg-interferon-alpha-konjugaten und raffinose als kryoschutzmittel
RU2469739C2 (ru) *	2007-04-26	2012-12-20	БАЙЕР ХЕЛСКЕА ЛЛСи	Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
AU2013204652B2 (en) *	2007-04-26	2015-06-18	Bayer Healthcare Llc	Stabilization of liquid solutions of recombinant protein for frozen storage
KR101491995B1 (ko) *	2007-05-08	2015-02-10	아지노모토 가부시키가이샤	저지방 식품
US9101691B2 (en)	2007-06-11	2015-08-11	Edwards Lifesciences Corporation	Methods for pre-stressing and capping bioprosthetic tissue
US9034818B2 (en) *	2007-06-13	2015-05-19	Novo Nordisk A/S	Pharmaceutical formulations comprising an insulin derivative
GB0715285D0 (en) *	2007-08-06	2007-09-12	Britannia Pharmaceuticals Ltd	Improvements in or relating to powdered medicaments for nasal delivery
CN101376022B (zh) *	2007-08-31	2011-11-30	上海医药工业研究院	含聚乙二醇降纤酶的药物组合物
US8357387B2 (en)	2007-12-21	2013-01-22	Edwards Lifesciences Corporation	Capping bioprosthetic tissue to reduce calcification
AU2008340304B2 (en) *	2007-12-21	2016-03-03	Aptevo Biotherapeutics Llc	Stabilized factor IX formulations containing trehalose
PL2235197T3 (pl)	2007-12-27	2018-01-31	Baxalta GmbH	Sposoby hodowli komórek
EP2113564A1 (de) *	2008-05-01	2009-11-04	Arecor Limited	Proteinformulierung
ES2968301T3 (es) *	2008-08-05	2024-05-08	Wyeth Llc	Liofilización por encima del colapso
CN102119172A (zh)	2008-08-21	2011-07-06	奥克塔法马股份有限公司	重组制备的人类因子viii和ix
CA2734919C (en) *	2008-08-27	2016-08-16	Schering Corporation	Lyophilized formulations of engineered anti-il-23p19 antibodies
US20110178019A1 (en) *	2008-09-03	2011-07-21	Brita Rippner	New protecting compositions for recombinantly produced factor viii
BRPI0918978A2 (pt) *	2008-09-10	2015-12-01	Genentech Inc	composições e métodos a prevenção da degradação oxidativa das proteínas
AU2009309623B9 (en) *	2008-10-30	2014-10-02	Novo Nordisk A/S	Treating diabetes melitus using insulin injections with less than daily injection frequency
NZ593190A (en) *	2008-11-07	2013-01-25	Baxter Int	Factor viii formulations
EP2248518B1 (de) *	2009-04-17	2013-01-16	Merz Pharma GmbH & Co. KGaA	Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen.
US8809501B2 (en)	2009-07-27	2014-08-19	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
CN106110311A (zh)	2009-07-27	2016-11-16	百深公司	凝血蛋白缀合物
KR101912335B1 (ko)	2009-07-27	2018-10-26	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
CN102497884A (zh)	2009-07-27	2012-06-13	巴克斯特国际公司	凝血蛋白缀合物
US8642737B2 (en)	2010-07-26	2014-02-04	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
GB0915480D0 (en)	2009-09-04	2009-10-07	Arecor Ltd	Stable formulation of factor viii
HUE028688T2 (en)	2009-09-21	2017-01-30	Baxalta GmbH	Stabilized liquid and lyophilized adamts13 formulations
TR201809898T4 (tr)	2009-11-03	2018-07-23	Grifols Therapeutics Llc	Alfa-1 protei̇naz i̇nhi̇bi̇törüne yöneli̇k bi̇leşi̇m, yöntem ve ki̇t.
PT2503995T (pt) *	2009-11-24	2017-11-23	Grifols Therapeutics Inc	Métodos de liofilização, composições e kits
KR101335765B1 (ko) *	2010-01-19	2013-12-02	한미사이언스 주식회사	지속형 에리스로포이에틴 결합체의 액상 제제
EP3636293A1 (de)	2010-03-23	2020-04-15	Edwards Lifesciences Corporation	Verfahren zur bearbeitung eines scheibenförmigen bioprothese-gewebes
WO2011160085A2 (en)	2010-06-17	2011-12-22	Edwards Lifesciences Corporation	Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
US8906601B2 (en)	2010-06-17	2014-12-09	Edwardss Lifesciences Corporation	Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
CA2810731A1 (en) *	2010-09-17	2012-03-22	Baxter International Inc.	Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
JP5990176B2 (ja)	2010-10-12	2016-09-07	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP5922141B2 (ja)	2010-11-05	2016-05-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
US9351829B2 (en)	2010-11-17	2016-05-31	Edwards Lifesciences Corporation	Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
US20130345403A1 (en) *	2010-12-16	2013-12-26	Novo Nordisk A/S	Aqueous factor viii solution
HUE049352T2 (hu)	2010-12-22	2020-09-28	Baxalta GmbH	Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
BRPI1105317A2 (pt)	2011-01-24	2013-04-30	Fundacco Hemoct De Ribeirco Preto	produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
ES2676205T3 (es)	2011-03-31	2018-07-17	Merck Sharp & Dohme Corp.	Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
JP6060447B2 (ja)	2011-04-08	2017-01-18	バイオ−ラッドラボラトリーズインコーポレーティッド	非特異的活性が低下したＳｓｏ７ポリメラーゼコンジュゲート
SG193990A1 (en)	2011-04-08	2013-11-29	Bio Rad Laboratories	Pcr reaction mixtures with decreased non-specific activity
WO2014031718A1 (en)	2012-08-23	2014-02-27	Merck Sharp & Dohme Corp.	Stable formulations of antibodies to tslp
US10238771B2 (en)	2012-11-08	2019-03-26	Edwards Lifesciences Corporation	Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US20160030524A1 (en) *	2013-03-15	2016-02-04	Bayer Healthcare Llc	Recombinant factor viii formulations
DK2968477T3 (da) *	2013-03-15	2020-03-09	Bioverativ Therapeutics Inc	Faktor viii-polypeptidformuleringer
US9839579B2 (en)	2013-04-24	2017-12-12	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2016519127A (ja)	2013-04-30	2016-06-30	ノヴォノルディスクアー／エス	新規投与レジメン
KR102058864B1 (ko) *	2013-12-16	2019-12-24	주식회사 티움바이오	인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
CA2944349A1 (en)	2014-04-01	2015-10-08	Advantech Bioscience Farmaceutica Ltda.	Stable factor viii formulations with low sugar-glycine
JP2017509658A (ja) *	2014-04-01	2017-04-06	アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ	カルシウム添加剤を使用しない第ｖｉｉｉ因子の安定化
US10238718B2 (en) *	2014-08-04	2019-03-26	Csl Limited	Factor VIII formulation
KR20250150675A (ko) *	2014-08-20	2025-10-20	포톨라 파마슈티컬스, 인코포레이티드	인자 xa 해독제용 동결건조된 제형
CN114129709A (zh) *	2014-10-23	2022-03-04	恩格姆生物制药公司	包含肽变异体的药物组合物及其使用方法
ES2893239T3 (es)	2015-04-21	2022-02-08	Staidson Beijing Biopharmaceuticals Co Ltd	Composición de factor de crecimiento nervioso y polvo de inyección
CN107660149B (zh)	2015-04-21	2021-04-27	舒泰神（北京）生物制药股份有限公司	一种神经生长因子组合物及注射粉剂
WO2017007837A1 (en) *	2015-07-07	2017-01-12	Nanobio Corporation	Methods and compositions for the stabilizaton of proteins
US11173197B2 (en)	2015-07-07	2021-11-16	Bluewillow Biologics, Inc.	Methods and compositions for nanoemulsion vaccine formulations
WO2017011275A1 (en) *	2015-07-10	2017-01-19	Nersissian Aram M	Factor viii protein compositions and methods of treating hemophilia a
EP3167877A1 (de) *	2015-11-12	2017-05-17	Bayer Pharma Aktiengesellschaft	Verfahren zur herstellung von gefriergetrockneten pellets mit faktor viii
CN108883160B (zh)	2016-02-24	2022-06-28	博尔托拉制药公司	因子xa解毒剂的冻干制剂
KR102783452B1 (ko) *	2016-06-01	2025-03-19	세르비에 아이피 유케이 리미티드	폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
WO2018112780A1 (en) *	2016-12-21	2018-06-28	Chung Chin Sun	Novel method for blood plasma protein activity preservation
AU2018263868A1 (en)	2017-05-02	2019-12-12	Merck Sharp & Dohme Llc	Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP6630315B2 (ja)	2017-06-27	2020-01-15	矢崎総業株式会社	ノイズ低減ユニット
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102885113B1 (ko)	2018-10-18	2025-11-13	머크 샤프 앤드 돔 엘엘씨	항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh)	2018-10-31	2025-10-28	默沙东有限责任公司	抗人pd-1抗体晶体及其使用方法
CN113316458B (zh)	2018-11-07	2024-08-02	默沙东有限责任公司	抗lag3抗体和抗pd-1抗体的共制剂
US20220305094A1 (en) *	2019-01-06	2022-09-29	Endo Global Aesthetics Limited	Collagenase formulations and methods of producing the same
CN114072420B (zh)	2019-07-04	2024-06-11	康诺贝林伦瑙有限公司	用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
CN110772487B (zh) *	2019-12-09	2021-09-21	湖南科伦制药有限公司	一种二乙酰氨乙酸乙二胺的冻干方法
IL301533A (en)	2020-09-24	2023-05-01	Merck Sharp ַ& Dohme Llc	Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
CN112121009B (zh) *	2020-09-24	2022-12-02	科兴生物制药股份有限公司	一种聚乙二醇修饰重组人粒细胞刺激因子新制剂
CN116322920A (zh)	2020-11-09	2023-06-23	武田药品工业株式会社	使用氧化硅吸附从血浆中纯化fviii
US20230030281A1 (en) *	2021-04-09	2023-02-02	Hyalo Technologies, LLC	Method of sterilization of biologics
US20220323621A1 (en) *	2021-04-09	2022-10-13	Hyalo Technologies, LLC	Method of sterilization of biologics
US20240342254A1 (en) *	2021-08-11	2024-10-17	Grifols Worldwide Operations Limited	Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained
CN114015758B (zh) *	2021-10-15	2022-06-24	无锡百泰克生物技术有限公司	一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB941019A (en)	1961-04-27	1963-11-06	Crookes Lab Ltd	Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
US3389314A (en)	1962-05-07	1968-06-18	Penn Controls	Proportional silicon controlled rectifier driven system for a heat motor
US3681126A (en)	1969-11-25	1972-08-01	Monsanto Co	Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride
US3770631A (en)	1971-06-29	1973-11-06	Baxter Laboratories Inc	Clarification of blood serum and plasma
US3839314A (en)	1971-06-29	1974-10-01	Baxter Laboratories Inc	Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4073886A (en)	1973-01-30	1978-02-14	Baxter Travenol Laboratories, Inc.	Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3980432A (en)	1973-04-02	1976-09-14	Behringwerke Aktiengesellschaft	Partial thromboplastin, its use as diagnostic agent and process for preparing it
US3893990A (en)	1973-04-05	1975-07-08	Baxter Laboratories Inc	Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3893991A (en)	1973-04-05	1975-07-08	Baxter Laboratories Inc	Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4086218A (en)	1975-04-11	1978-04-25	Edward Shanbrom, Inc.	Method of preserving blood plasma II
US4189425A (en)	1975-04-11	1980-02-19	Edward Shanbrom, Inc.	Method of preserving blood plasma I
US4069216A (en)	1975-06-16	1978-01-17	Edward Shanbrom, Inc.	Simplified methods for preparation of very high purity Factor VIII concentrate
US4089944A (en)	1975-12-22	1978-05-16	Baxter Travenol Laboratories, Inc.	Rapidly solubilized AHF composition and process for preparing same
US4027013A (en)	1976-01-22	1977-05-31	William L. Wilson	Clottable fibrinogen free factor VIII and albumin product and process
SU663404A1 (ru)	1976-12-30	1979-05-25	Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова	Способ получени фибрин-мономера
US4137223A (en)	1977-05-16	1979-01-30	Edward Shanbrom, Inc.	Method of preserving blood plasma II
SE443293B (sv)	1978-01-25	1986-02-24	Blombaeck E G B	Blodfraktionsframstellning
DE2916711A1 (de)	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en)	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
FR2460305A2 (fr)	1979-06-29	1981-01-23	Merieux Inst	Procede de preparation d'un concentre de facteur viii
US4386068A (en)	1980-02-26	1983-05-31	Cutter Laboratories, Inc.	Antihemophilic factor concentrate and method for preparation
JPS56127308U (de)	1980-02-27	1981-09-28
EP0035204B2 (de)	1980-03-05	1991-05-22	Miles Inc.	Pasteurisierte therapeutisch aktive Proteinzusammensetzungen
US4341764A (en)	1980-03-05	1982-07-27	Cutter Laboratories, Inc.	Method of preparing fibronectin and antihemophilic factor
US4440679A (en)	1980-03-05	1984-04-03	Cutter Laboratories, Inc.	Pasteurized therapeutically active protein compositions
US4623717A (en)	1980-03-05	1986-11-18	Miles Laboratories, Inc.	Pasteurized therapeutically active protein compositions
JPS56127308A (en)	1980-03-11	1981-10-06	Green Cross Corp:The	Blood-coagulation factor 8 pharmaceutical
JPS56135418A (en)	1980-03-27	1981-10-22	Green Cross Corp:The	Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
AT369263B (de)	1980-08-27	1982-12-27	Immuno Ag	Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
DE3033932C2 (de)	1980-09-10	1984-05-24	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
JPS5770814A (en)	1980-10-17	1982-05-01	Isamu Horikoshi	Oral preparation of blood clotting eighth factor
JPS6122022Y2 (de)	1981-01-10	1986-07-02
US4495278A (en)	1981-04-27	1985-01-22	Baxter Travenol Laboratories, Inc.	Process for making novel blood clotting enzyme compositions
US4382083A (en)	1981-06-25	1983-05-03	Baxter Travenol Laboratories, Inc.	Therapeutic method for treating blood-clotting defects with factor VIIa
US4479938A (en)	1981-06-25	1984-10-30	Baxter Travenol Laboratories, Inc.	Therapeutic composition containing factor VIIa
JPS5874617A (ja)	1981-10-28	1983-05-06	Green Cross Corp:The	人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en)	1981-11-02	1989-05-30		Heat treatment of lyphilized blood clotting factor viii concentrate
US4591505A (en)	1982-04-14	1986-05-27	New York Blood Center, Inc.	Process for inactivating hepatitis B virus
US4481189A (en)	1982-04-14	1984-11-06	New York Blood Center Inc.	Process for preparing sterilized plasma and plasma derivatives
US4495175A (en)	1982-08-05	1985-01-22	University Of Rochester	Preparation of highly purified human antihemophilic factor
DE3230849A1 (de)	1982-08-19	1984-02-23	Behringwerke Ag, 3550 Marburg	Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
DE3237512A1 (de)	1982-10-09	1984-04-12	Behringwerke Ag, 3550 Marburg	Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
GB2129685B (en)	1982-11-11	1985-11-13	Nat Biolog Standards Board	Anti-haemophilic compositions
JPS59134730A (ja)	1983-01-20	1984-08-02	Green Cross Corp:The	血液凝固第８因子の加熱処理法
NO167533C (no)	1983-03-31	1991-11-13	Scripps Clinic Res	Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
US4748120A (en)	1983-05-02	1988-05-31	Diamond Scientific Co.	Photochemical decontamination treatment of whole blood or blood components
US4727027A (en)	1983-05-02	1988-02-23	Diamond Scientific Co.	Photochemical decontamination treatment of whole blood or blood components
DE3481109D1 (de)	1983-05-09	1990-03-01	Novo Nordisk As	Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
AT379510B (de)	1983-05-20	1986-01-27	Immuno Ag	Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
DE3318521A1 (de)	1983-05-20	1984-11-22	Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München	Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats
US4540573A (en)	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
DE3336631A1 (de)	1983-10-08	1985-04-18	Behringwerke Ag, 3550 Marburg	Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4693981A (en)	1983-12-20	1987-09-15	Advanced Genetics Research Institute	Preparation of inactivated viral vaccines
JPS6122022A (ja)	1983-12-28	1986-01-30	Green Cross Corp:The	血漿蛋白の加熱処理方法
DE10399011I1 (de)	1984-01-12	2003-10-23	Chiron Corp	F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
AT389815B (de)	1984-03-09	1990-02-12	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4831012A (en)	1984-03-23	1989-05-16	Baxter International Inc.	Purified hemoglobin solutions and method for making same
JPS60199829A (ja)	1984-03-24	1985-10-09	Nippon Sekijiyuujishiya	高純度抗血友病グロブリンの製造方法
US5043428A (en)	1984-08-31	1991-08-27	Behringwerke Aktiengesellschaft	Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US4543210A (en)	1984-10-04	1985-09-24	Miles Laboratories, Inc.	Process for producing a high purity antihemophilic factor concentrate
US4613501A (en)	1984-12-21	1986-09-23	New York Blood Center, Inc.	Inactivation of viruses in labile blood derivatives
JPS61271222A (ja) *	1985-05-24	1986-12-01	Dainippon Pharmaceut Co Ltd	ヒトインターロイキン１ポリペプチド及びその製造法
US4743680A (en)	1985-02-01	1988-05-10	New York University	Method for purifying antihemophilic factor
US4952675A (en)	1985-02-01	1990-08-28	New York University	Method for purifying antihemophilic factor
US4847362A (en)	1985-02-01	1989-07-11	New York University	Method for purifying antihemophilic factor
ATE72838T1 (de)	1985-04-12	1992-03-15	Genetics Inst	Neue prokoagulierungsproteine.
ATE68524T1 (de)	1985-07-09	1991-11-15	Quadrant Bioresources Ltd	Beschuetzung von proteinen und aehnlichem.
US4758657A (en)	1985-07-11	1988-07-19	Armour Pharmaceutical Company	Method of purifying Factor VIII:C
EP0212040B1 (de)	1985-08-05	1990-05-23	IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte	Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
AU6487286A (en)	1985-11-08	1987-05-14	Baxter Travenol Laboratories Inc.	Antihemophilic factor by cold precipitation
US5180583A (en)	1985-11-26	1993-01-19	Hedner Ulla K E	Method for the treatment of bleeding disorders
JPS62195331A (ja)	1986-02-24	1987-08-28	Nippon Sekijiyuujishiya	血液凝固第８因子製剤の製法
AT390374B (de)	1986-03-18	1990-04-25	Schwab & Co Gmbh	Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen
DE3609431A1 (de)	1986-03-20	1987-09-24	Biotest Pharma Gmbh	Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates
JPH0441740Y2 (de)	1986-05-30	1992-09-30
US4841023A (en)	1986-06-25	1989-06-20	New York Blood Center, Inc.	Inactivation of viruses in labile protein-containing compositions using fatty acids
AT391808B (de)	1986-11-03	1990-12-10	Immuno Ag	Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
GB8628104D0 (en)	1986-11-25	1986-12-31	Connaught Lab	Pasteurization of immunoglobin solutions
CA1331157C (en)	1987-04-06	1994-08-02	Randal J. Kaufman	Method for producing factor viii:c-type proteins
ES2006632A6 (es)	1987-04-21	1989-05-01	Green Cross Corp	Procedimiento de tratamiento termico de fibrinogeno.
IL86417A (en)	1987-05-22	1992-09-06	Armour Pharma	Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
US4876241A (en)	1987-05-22	1989-10-24	Armour Pharmaceutical Company	Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4795806A (en)	1987-07-16	1989-01-03	Miles Laboratories, Inc.	Phospholipid affinity purification of Factor VIII:C
JPH0387173A (ja)	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DE3730533A1 (de)	1987-09-11	1989-03-30	Biotest Pharma Gmbh	Verfahren zur sterilisation von plasma oder plasmafraktionen
KR890004724A (ko) *	1987-09-17	1989-05-09	히사시 미하라	신규 프로테아제 제제(製劑)
US5605884A (en)	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
CA1329760C (en) *	1987-10-29	1994-05-24	Ted C. K. Lee	Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
US5177191A (en)	1987-12-21	1993-01-05	Miles, Inc.	Gel filtration of factor VIII
DK18288D0 (da)	1988-01-15	1988-01-15	Nordisk Gentofte	Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
WO1989009784A1 (en)	1988-04-08	1989-10-19	Commonwealth Serum Laboratories Commission	Production of heat-stable factor viii concentrate
US4981951A (en)	1988-04-14	1991-01-01	Miles Inc.	Lectin affinity chromatography of factor VIII
FR2632309B1 (fr)	1988-06-07	1990-08-24	Lille Transfusion Sanguine	Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US5047249A (en)	1988-07-22	1991-09-10	John Morris Co., Inc.	Compositions and methods for treating skin conditions and promoting wound healing
US5051353A (en)	1988-08-09	1991-09-24	The United States Of America As Represented By The Secretary Of The Navy	Preservation and restoration of hemoglobin in blood substitutes
JPH02157231A (ja) *	1988-12-07	1990-06-18	Bio Kagaku Kenkyusho:Kk	細胞増殖抑制剤
DE3904354A1 (de)	1989-02-14	1990-08-16	Behringwerke Ag	Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr)	1990-08-02	1995-04-14	Aquitaine Developp Transf Sang	Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
US5760183A (en)	1989-02-17	1998-06-02	Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques	Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
CN1047342A (zh)	1989-05-13	1990-11-28	杭州市中心血站	因子viii的生产及其病毒灭活方法
ATE90875T1 (de)	1989-05-24	1993-07-15	Miles Inc	Gelfiltration von waermebehandeltem faktor viii.
GB8913183D0 (en) *	1989-06-08	1989-07-26	Central Blood Lab Authority	Chemical products
US5138034A (en)	1989-07-12	1992-08-11	The Green Cross Corporation	Method of fractionating plasma proteins
US5062498A (en)	1989-07-18	1991-11-05	Jaromir Tobias	Hydrostatic power transfer system with isolating accumulator
DE69029765T2 (de)	1989-07-24	1997-05-15	Bayer Ag	Stabilisierung von hochgereinigten Proteinen
DE3926034C3 (de)	1989-08-07	1996-11-21	Behringwerke Ag	Verfahren zur Herstellung eines stabilen Faktors VIII
FR2651437A1 (fr)	1989-09-05	1991-03-08	Lille Transfusion Sanguine	Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DK162233C (da)	1989-11-09	1992-03-16	Novo Nordisk As	Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
SE465222C5 (sv)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5439882A (en)	1989-12-29	1995-08-08	Texas Tech University Health Sciences Center	Blood substitute
DE4001451A1 (de)	1990-01-19	1991-08-01	Octapharma Ag	Stabile injizierbare loesungen von faktor viii und faktor ix
US5418130A (en)	1990-04-16	1995-05-23	Cryopharm Corporation	Method of inactivation of viral and bacterial blood contaminants
US5798238A (en)	1990-04-16	1998-08-25	Baxter International Inc.	Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US5587490A (en)	1990-04-16	1996-12-24	Credit Managers Association Of California	Method of inactivation of viral and bacterial blood contaminants
AU7875791A (en) *	1990-05-07	1991-11-27	Exxon Chemical Patents Inc.	Unsaturated alpha-olefin copolymers and method for preparation thereof
US5378612A (en)	1990-05-11	1995-01-03	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Culture medium for production of recombinant protein
US5712086A (en)	1990-05-15	1998-01-27	New York Blood Center, Inc.	Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5232844A (en)	1990-05-15	1993-08-03	New York Blood Center	Photodynamic inactivation of viruses in cell-containing compositions
FR2662166A1 (fr)	1990-05-18	1991-11-22	Fondation Nale Transfusion San	Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
IT1248723B (it)	1990-06-12	1995-01-26	Scalvo S P A	Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
DE69111399T2 (de)	1990-07-12	1996-02-29	Baxter Diagnostics Inc., Deerfield, Ill.	Chromogenes bestimmungsverfahren für den faktor viii:ca.
CA2051092C (en)	1990-09-12	2002-07-23	Stephen A. Livesey	Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
FR2673632A1 (fr)	1991-03-08	1992-09-11	Lille Transfusion Sanguine	Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4111393A1 (de) *	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
SE468480B (sv)	1991-05-24	1993-01-25	Arne Holmgren	Modifierat tioredoxin och dess anvaendning
AU2309692A (en)	1991-07-03	1993-02-11	Cryolife, Inc.	Method for stabilization of biomaterials
US5254350A (en)	1991-07-22	1993-10-19	Helena Laboratories Corporation	Method of preparing a thromboplastin extract
CA2078721A1 (en)	1991-09-24	1993-03-25	Hiroshi Yonemura	Process for preparing human coagulation factor viii protein complex
FR2681867B1 (fr)	1991-09-26	1993-12-31	Pasteur Merieux Serums Vaccins	Procede de purification du facteur viii et preparations obtenues.
US5278289A (en)	1991-11-12	1994-01-11	Johnson Alan J	Antihemophilic factor stabilization
US5192743A (en)	1992-01-16	1993-03-09	Genentech, Inc.	Reconstitutable lyophilized protein formulation
JPH05331071A (ja) *	1992-01-17	1993-12-14	Asahi Chem Ind Co Ltd	カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
AT399818B (de)	1992-04-24	1995-07-25	Immuno Ag	Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
US5288853A (en)	1992-04-30	1994-02-22	Alpha Therapeutic Corporation	Factor viii purification process
WO1993022336A1 (en)	1992-04-30	1993-11-11	Alpha Therapeutic Corporation	Improved solubilization and stabilization of factor viii complex
US5378601A (en)	1992-07-24	1995-01-03	Montefiore Medical Center	Method of preserving platelets with apyrase and an antioxidant
US5424471A (en) *	1992-07-31	1995-06-13	U.S. Bioscience, Inc.	Crystalline amifostine compositions and methods of the preparation and use of same
SE9302006D0 (sv) *	1992-10-02	1993-06-11	Kabi Pharmacia Ab	Protein formulation
DE69329795T2 (de) *	1992-10-02	2001-07-05	Genetics Institute, Inc.	Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
IT1256622B (it)	1992-12-04	1995-12-12	Sclavo Spa	Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4242863A1 (de) *	1992-12-18	1994-06-23	Boehringer Mannheim Gmbh	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
ES2118386T3 (es)	1993-02-09	1998-09-16	Octapharma Ag	Procedimiento para la inactivacion de virus que no estan provistos de envolventes lipidicas.
SE9301581D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Protein formulation
SE504074C2 (sv)	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5576291A (en)	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5353835A (en)	1993-09-23	1994-10-11	Ingersoll-Rand Company	Air tank drain
IT1268920B1 (it)	1994-03-29	1997-03-13	Syfal Srl	Macchina rotativa per la decorazione-smaltatura in particolare dipiastrelle ceramiche.
IL113010A0 (en)	1994-03-31	1995-10-31	Pharmacia Ab	Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en)	1994-04-11	1996-05-07	Bayer Corporation	Use of azoles as virucidal agents in solutions of biologically active proteins
US5955448A (en)	1994-08-19	1999-09-21	Quadrant Holdings Cambridge Limited	Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
FR2719479B1 (fr) *	1994-05-04	1996-07-26	Sanofi Elf	Formulation stable lyophilisée comprenant une protéine: kit de dosage.
CN1188171C (zh)	1994-06-02	2005-02-09	廓德伦特控股剑桥有限公司	防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
US5580856A (en)	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
DE4431833C1 (de)	1994-09-07	1995-05-18	Blutspendedienst Der Drk Lande	Verfahren zur Herstellung eines AHF-Konzentrates
GB2293100A (en)	1994-09-15	1996-03-20	Medeva Europ Ltd	Pharmaceutical compositions with deuterium oxide
SE503424C2 (sv)	1994-11-14	1996-06-10	Pharmacia Ab	Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv)	1994-11-14	1994-11-14	Annelie Almstedt	Process A
WO1996019918A1 (en) *	1994-12-28	1996-07-04	Biotime, Inc.	Plasma expanders and blood substitutes
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
SE9501189D0 (sv) *	1995-03-31	1995-03-31	Pharmacia Ab	Protein formulation
US5679549A (en)	1995-05-04	1997-10-21	Bayer Corporation	Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition
JP3927248B2 (ja) *	1995-07-11	2007-06-06	第一製薬株式会社	Ｈｇｆ凍結乾燥製剤
KR0167677B1 (ko) *	1995-08-31	1999-02-01	김광호	다중 비트 테스트를 위한 패턴 발생기를 가지는 메모리 테스트 시스템
SE9503380D0 (sv)	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
ES2099678B1 (es)	1995-11-03	1998-02-16	Grifols Grupo Sa	Procedimiento para la inactivacion de virus en proteinas.
ATE235814T1 (de)	1995-11-06	2003-04-15	New York Blood Ct Inc	Behandlung von roten blutzellen zur inaktivierung von virien durch verwendung von pathalocyanine und rotlicht
US5659017A (en)	1995-11-07	1997-08-19	Alpha Therapeutic Corporation	Anion exchange process for the purification of Factor VIII
US5925738A (en)	1995-12-01	1999-07-20	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
US5851800A (en)	1996-05-14	1998-12-22	Pharmacia & Upjohn Ab	Process for producing a protein
US6632648B1 (en)	1996-05-14	2003-10-14	Elan Drug Delivery Limited	Methods of terminal sterilization of fibrinogen
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP2921180B1 (de) *	1999-02-22	2019-08-14	University of Connecticut	Albuminfreie Faktor-VIII-Formulierungen
DK1194161T3 (da)	1999-07-13	2006-02-13	Biovitrum Ab	Stabile faktor VIII-sammensatninger
US6440414B1 (en) *	1999-10-01	2002-08-27	Amgen Inc.	Pharmaceutical compositions of fibrinolytic agent
RU2373953C2 (ru)	2003-12-19	2009-11-27	Ново Нордиск Хелс Кеа Аг	Стабилизированная композиция, содержащая полипептид фактора vii
US9084777B2 (en)	2005-12-28	2015-07-21	Chugai Seiyaku Kabushiki Kaisha	Stabilized antibody-containing formulations
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US20110178019A1 (en)	2008-09-03	2011-07-21	Brita Rippner	New protecting compositions for recombinantly produced factor viii

2000
- 2000-02-22 EP EP15154020.0A patent/EP2921180B1/de not_active Expired - Lifetime
- 2000-02-22 ES ES09075396T patent/ES2394755T3/es not_active Expired - Lifetime
- 2000-02-22 EP EP09075396A patent/EP2130554B1/de not_active Revoked
- 2000-02-22 CN CN200910171121A patent/CN101810854A/zh active Pending
- 2000-02-22 MX MXPA01008515A patent/MXPA01008515A/es active IP Right Grant
- 2000-02-22 CA CA2362927A patent/CA2362927C/en not_active Expired - Lifetime
- 2000-02-22 EP EP06077229.0A patent/EP1820516B1/de not_active Expired - Lifetime
- 2000-02-22 PL PL382288A patent/PL203177B1/pl unknown
- 2000-02-22 PL PL382299A patent/PL203893B1/pl unknown
- 2000-02-22 AT AT00907322T patent/ATE365052T1/de active
- 2000-02-22 ES ES00907322T patent/ES2288843T3/es not_active Expired - Lifetime
- 2000-02-22 CA CA002634663A patent/CA2634663C/en not_active Expired - Lifetime
- 2000-02-22 DK DK00907322T patent/DK1154796T3/da active
- 2000-02-22 DK DK06077229.0T patent/DK1820516T3/da active
- 2000-02-22 CZ CZ2008-828A patent/CZ307715B6/cs not_active IP Right Cessation
- 2000-02-22 AU AU28843/00A patent/AU777972B2/en not_active Expired
- 2000-02-22 CA CA002634674A patent/CA2634674A1/en not_active Abandoned
- 2000-02-22 BR BRPI0008405-0B1A patent/BR0008405B1/pt not_active IP Right Cessation
- 2000-02-22 CZ CZ20012996A patent/CZ300547B6/cs not_active IP Right Cessation
- 2000-02-22 RU RU2001125929/15A patent/RU2244556C2/ru active
- 2000-02-22 EP EP00907322A patent/EP1154796B1/de not_active Expired - Lifetime
- 2000-02-22 EP EP10075019.9A patent/EP2193809B1/de not_active Expired - Lifetime
- 2000-02-22 JP JP2000599425A patent/JP5149470B2/ja not_active Expired - Lifetime
- 2000-02-22 WO PCT/US2000/040068 patent/WO2000048635A1/en not_active Ceased
- 2000-02-22 PT PT60772290T patent/PT1820516E/pt unknown
- 2000-02-22 DE DE60035260T patent/DE60035260T2/de not_active Expired - Lifetime
- 2000-02-22 ES ES06077229T patent/ES2435141T3/es not_active Expired - Lifetime
- 2000-02-22 DK DK09075396.3T patent/DK2130554T3/da active
- 2000-02-22 DK DK10075019.9T patent/DK2193809T3/en active
- 2000-02-22 PL PL382300A patent/PL204701B1/pl unknown
- 2000-02-22 CZ CZ2008-827A patent/CZ307322B6/cs not_active IP Right Cessation
- 2000-02-22 CA CA2634664A patent/CA2634664C/en not_active Expired - Lifetime
- 2000-02-22 PT PT09075396T patent/PT2130554E/pt unknown
- 2000-02-22 PT PT00907322T patent/PT1154796E/pt unknown
- 2000-02-22 US US09/507,011 patent/US6586573B1/en not_active Expired - Lifetime
- 2000-02-22 PL PL356453A patent/PL198123B1/pl unknown
- 2000-02-22 CN CNB008063044A patent/CN100553678C/zh not_active Expired - Lifetime
- 2000-02-22 ES ES10075019.9T patent/ES2541470T3/es not_active Expired - Lifetime
- 2000-02-22 CN CN2009101711245A patent/CN101683522B/zh not_active Expired - Lifetime
- 2000-02-22 PT PT100750199T patent/PT2193809E/pt unknown
2003
- 2003-07-01 US US10/610,723 patent/US7087723B2/en not_active Expired - Lifetime
2006
- 2006-05-15 US US11/434,634 patent/US7247707B2/en not_active Expired - Lifetime
2007
- 2007-06-18 US US11/764,770 patent/US8058226B2/en not_active Expired - Lifetime
- 2007-08-07 CY CY20071101050T patent/CY1108030T1/el unknown
2008
- 2008-05-01 JP JP2008120035A patent/JP5006832B2/ja not_active Expired - Lifetime
- 2008-09-30 JP JP2008255510A patent/JP5140539B2/ja not_active Expired - Lifetime
2011
- 2011-09-30 US US13/250,789 patent/US8372800B2/en not_active Expired - Fee Related
2012
- 2012-01-20 JP JP2012009767A patent/JP5596064B2/ja not_active Expired - Lifetime
- 2012-12-04 CY CY20121101185T patent/CY1113969T1/el unknown
2013
- 2013-02-06 US US13/760,900 patent/US8765665B2/en not_active Expired - Lifetime
- 2013-11-01 JP JP2013227977A patent/JP6038003B2/ja not_active Expired - Lifetime
2014
- 2014-05-23 US US14/286,391 patent/US9352027B2/en not_active Expired - Fee Related
2015
- 2015-02-20 JP JP2015031316A patent/JP6155442B2/ja not_active Expired - Lifetime
- 2015-11-11 JP JP2015220875A patent/JP6253627B2/ja not_active Expired - Lifetime
2016
- 2016-02-18 HK HK16101857.2A patent/HK1213801A1/en unknown
- 2016-05-04 US US15/146,835 patent/US9669076B2/en not_active Expired - Fee Related
2017
- 2017-04-27 JP JP2017088289A patent/JP2017125076A/ja not_active Withdrawn
2018
- 2018-07-02 JP JP2018125917A patent/JP2018172413A/ja active Pending

Also Published As

Publication number	Publication date
US6586573B1 (en)	2003-07-01
CA2362927A1 (en)	2000-08-24
AU777972B2 (en)	2004-11-04
CZ20012996A3 (cs)	2002-03-13
EP1820516A2 (de)	2007-08-22
CZ307715A3 (cs)	2002-03-13
DK2130554T3 (da)	2012-12-03
BR0008405B1 (pt)	2014-04-22
CZ307322B6 (cs)	2018-06-06
US20060205661A1 (en)	2006-09-14
PL203893B1 (pl)	2009-11-30
CN100553678C (zh)	2009-10-28
AU2884300A (en)	2000-09-04
EP2130554A1 (de)	2009-12-09
CZ300547B6 (cs)	2009-06-10
CZ307715B6 (cs)	2019-03-06
US20170000854A1 (en)	2017-01-05
PL204701B1 (pl)	2010-02-26
DK1820516T3 (da)	2013-10-28
US20150025010A1 (en)	2015-01-22
JP2003520764A (ja)	2003-07-08
HK1133583A1 (en)	2010-04-01
EP2921180B1 (de)	2019-08-14
JP2015091902A (ja)	2015-05-14
JP2014024864A (ja)	2014-02-06
ES2394755T3 (es)	2013-02-05
EP1154796B1 (de)	2007-06-20
US7087723B2 (en)	2006-08-08
CA2634663C (en)	2009-08-25
ES2435141T3 (es)	2013-12-18
JP5149470B2 (ja)	2013-02-20
JP5006832B2 (ja)	2012-08-22
DE60035260D1 (de)	2007-08-02
CA2634664C (en)	2011-08-09
CN101683522A (zh)	2010-03-31
EP1154796A1 (de)	2001-11-21
CN1399560A (zh)	2003-02-26
HK1139862A1 (en)	2010-09-30
US8058226B2 (en)	2011-11-15
ATE365052T1 (de)	2007-07-15
PT1820516E (pt)	2013-10-31
HK1213801A1 (en)	2016-07-15
CY1113969T1 (el)	2016-07-27
JP6038003B2 (ja)	2016-12-07
CA2362927C (en)	2011-07-12
US20080176791A1 (en)	2008-07-24
JP2017125076A (ja)	2017-07-20
US9352027B2 (en)	2016-05-31
DE60035260T2 (de)	2007-10-18
CA2634674A1 (en)	2000-08-24
PL198123B1 (pl)	2008-05-30
CA2634663A1 (en)	2000-08-24
WO2000048635A1 (en)	2000-08-24
JP2012072198A (ja)	2012-04-12
US8765665B2 (en)	2014-07-01
ES2541470T3 (es)	2015-07-20
CN101810854A (zh)	2010-08-25
JP6253627B2 (ja)	2017-12-27
ES2288843T3 (es)	2008-02-01
US8372800B2 (en)	2013-02-12
US20040116345A1 (en)	2004-06-17
PT2130554E (pt)	2012-11-19
PT2193809E (pt)	2015-08-24
US9669076B2 (en)	2017-06-06
EP2130554B1 (de)	2012-09-05
JP2009046499A (ja)	2009-03-05
PL203177B1 (pl)	2009-09-30
JP2008201801A (ja)	2008-09-04
CN101683522B (zh)	2013-05-01
CY1108030T1 (el)	2013-09-04
BR0008405A (pt)	2002-04-30
DK2193809T3 (en)	2015-05-26
PT1154796E (pt)	2007-09-28
JP6155442B2 (ja)	2017-07-05
JP2016040310A (ja)	2016-03-24
RU2244556C2 (ru)	2005-01-20
MXPA01008515A (es)	2003-06-06
JP5140539B2 (ja)	2013-02-06
US20130184216A1 (en)	2013-07-18
US20120083446A1 (en)	2012-04-05
JP2018172413A (ja)	2018-11-08
HK1106705A1 (en)	2008-03-20
US7247707B2 (en)	2007-07-24
CA2634664A1 (en)	2000-08-24
EP1820516B1 (de)	2013-07-24
JP5596064B2 (ja)	2014-09-24
EP1820516A3 (de)	2009-10-07
EP2193809B1 (de)	2015-04-08
EP2193809A1 (de)	2010-06-09
PL356453A1 (en)	2004-06-28
EP2921180A1 (de)	2015-09-23

Publication	Publication Date	Title
DK1154796T3 (da)	2007-09-24	Nye albuminfrie Faktor VIII-formuleringer
MEP33708A (hr)	2010-10-10	Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze
DK1246639T3 (da)	2007-06-11	GLP-2-formuleringer
RU2001125929A (ru)	2003-06-10	Новые не содержащие альбумин составы фактора viii
EP1389137A4 (de)	2005-01-05	Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
CO4600739A1 (es)	1998-05-08	Formulaciones liquidas orales a base de alendronato
ATE359824T1 (de)	2007-05-15	Wässrige formulierung enthaltend menschliches wachstumshormon
ATE464062T1 (de)	2010-04-15	Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
RU93043528A (ru)	1996-09-20	Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
NZ501346A (en)	2000-10-27	Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use
HRP20000181B1 (en)	2006-07-31	2-methyl-thieno-benzodiazepine formulation
NO20002232L (no)	2000-06-27	Antiperspirantaktive stoffer og formuleringer med slike
CA2326222A1 (en)	1999-11-04	Medicinal compositions
TR200002605T2 (tr)	2000-12-21	Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
AR012438A1 (es)	2000-10-18	Preparacion liquida antiacida libre de conservadores que es de ph estable, durante su vida de almacenamiento
DK1230236T3 (da)	2005-02-21	Forbindelse med væksthormonfrigörende egenskaber
EP1369119A4 (de)	2004-12-15	Mittel zur steurung der expression von il-12
YU46503A (sh)	2006-08-17	Farmaceutski oblik dronedarona za parenteralnu upotrebu
DE69113978D1 (de)	1995-11-23	Anti-hiv mittel.
NO20042459L (no)	2004-08-25	Vannbasert farmasoytiske formuleringer av vannloselige prodrug av propofol
UY27373A1 (es)	2003-02-28	Formulaciones de interferón beta-humano
BR9812385A (pt)	2000-09-12	Formulações parasiticidas
HU0102987D0 (en)	2001-09-28	Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
RU99118348A (ru)	2001-08-27	Средство для подавления роста сульфатвосстанавливающих бактерий